8-K Announcements
6Material company update
Apr 23, 2026·SEC
Material company update
Feb 10, 2026·SEC
Material company update
Jan 12, 2026·SEC
Edwards Lifesciences Corporation(EW)Earnings, Financials & Key Ratios
EW•NYSE
47.7× P/E·Price updated Jun 19, 2026
AboutEdwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Show more
- Revenue$6.07B+11.5%
- EBITDA$1.79B+16.9%
- Net Income$1.07B-74.3%
- EPS (Diluted)1.83-73.7%
- Gross Margin78.13%-1.7%
- EBITDA Margin29.55%+4.8%
- Operating Margin26.97%+6.4%
- Net Margin17.69%-76.9%
- ROE10.52%-78.8%
EW Key Insights
Edwards Lifesciences Corporation (EW) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Excellent 3Y average ROE of 27.6%
- ✓FCF machine: 22.0% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 2.3% through buybacks
- ✓Healthy 5Y average net margin of 35.9%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EW Price & Volume
Edwards Lifesciences Corporation (EW) stock price & volume — 10-year historical chart
Loading chart...
EW Growth Metrics
Edwards Lifesciences Corporation (EW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years9.3%
5 Years6.7%
3 Years4.08%
TTM11.21%
Profit CAGR
10 Years8.05%
5 Years5.45%
3 Years-10.98%
TTM-74.35%
EPS CAGR
10 Years9.33%
5 Years7.08%
3 Years-9.14%
TTM-73.74%
Return on Capital
10 Years20.94%
5 Years18.57%
3 Years15.48%
Last Year13.96%
EW Recent Earnings
Edwards Lifesciences Corporation (EW) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 23, 2026Metric
Actual
Est
EPS
$0.78+7.0%
$0.73
Rev
$1.6B+3.2%
$1.6B
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$0.58-6.1%
$0.62
Rev
$1.6B+1.5%
$1.5B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.67+12.4%
$0.60
Rev
$1.6B+3.7%
$1.5B
Q3 2025
Jul 24, 2025Metric
Actual
Est
EPS
$0.67+7.4%
$0.62
Rev
$1.5B+3.0%
$1.5B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 23, 2026 | $0.78vs $0.73+7.0% | $1.6Bvs $1.6B+3.2% |
| Q1 2026 | Feb 10, 2026 | $0.58vs $0.62-6.1% | $1.6Bvs $1.5B+1.5% |
| Q4 2025 | Oct 30, 2025 | $0.67vs $0.60+12.4% | $1.6Bvs $1.5B+3.7% |
| Q3 2025 | Jul 24, 2025 | $0.67vs $0.62+7.4% | $1.5Bvs $1.5B+3.0% |
Based on last 12 quarters of dataView full earnings history →
EW Peer Comparison
Edwards Lifesciences Corporation (EW) competitors in Cardiovascular and heart rhythm devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 | |
 ZBH | 17.22B | 87.97 | 24.78 | 7.2% | 9.05% | 5.77% | 0.59 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 |
Compare EW vs Peers
Edwards Lifesciences Corporation (EW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EW Income Statement
Edwards Lifesciences Corporation (EW) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 3.44B | 3.72B | 4.35B | 4.39B | 5.23B | 5.38B | 5.01B | 5.44B | 6.07B |
Revenue Growth % | 15.91% | 8.37% | 16.79% | 0.88% | 19.29% | 2.86% | -6.92% | 8.57% | 11.55% |
Cost of Goods Sold | 882.9M | 922.1M | 1.16B | 1.1B | 1.23B | 1.17B | 1.04B | 1.12B | 1.33B |
COGS % of Revenue | 25.7% | 24.77% | 26.57% | 25.06% | 23.43% | 21.69% | 20.7% | 20.54% | 21.87% |
Gross Profit | 2.55B▲ 0% | 2.8B▲ 9.7% | 3.19B▲ 14.0% | 3.29B▲ 3.0% | 4.01B▲ 21.9% | 4.22B▲ 5.2% | 3.97B▼ 5.8% | 4.32B▲ 8.8% | 4.74B▲ 9.7% |
Gross Margin % | 74.3% | 75.23% | 73.43% | 74.94% | 76.57% | 78.31% | 79.3% | 79.46% | 78.13% |
Gross Profit Growth % | 18.28% | 9.73% | 14% | 2.96% | 21.88% | 5.21% | -5.75% | 8.79% | 9.69% |
Operating Expenses | 1.54B | 1.71B | 1.99B | 1.99B | 2.4B | 2.51B | 2.55B | 2.94B | 3.1B |
OpEx % of Revenue | 44.9% | 45.89% | 45.88% | 45.4% | 45.79% | 46.69% | 50.81% | 54.11% | 51.17% |
Selling, General & Admin | 989.7M | 1.09B | 1.24B | 1.23B | 1.49B | 1.57B | 1.58B | 1.79B | 2.09B |
SG&A % of Revenue | 28.81% | 29.18% | 28.57% | 28.06% | 28.54% | 29.12% | 31.59% | 32.89% | 34.37% |
Research & Development | 552.6M | 622.2M | 752.7M | 760.7M | 903.1M | 945.2M | 962.9M | 1.05B | 1.08B |
R&D % of Revenue | 16.09% | 16.71% | 17.31% | 17.34% | 17.26% | 17.56% | 19.22% | 19.36% | 17.79% |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 101.1M | -59.9M |
Operating Income | 1.01B▲ 0% | 1.09B▲ 8.1% | 1.2B▲ 9.7% | 1.3B▲ 8.2% | 1.61B▲ 24.3% | 1.7B▲ 5.7% | 1.43B▼ 16.2% | 1.38B▼ 3.4% | 1.64B▲ 18.7% |
Operating Margin % | 29.4% | 29.34% | 27.55% | 29.55% | 30.78% | 31.63% | 28.49% | 25.35% | 26.97% |
Operating Income Growth % | 23.86% | 8.14% | 9.67% | 8.19% | 24.26% | 5.71% | -16.16% | -3.4% | 18.68% |
EBITDA | 1.09B | 1.17B | 1.31B | 1.43B | 1.77B | 1.87B | 1.57B | 1.53B | 1.79B |
EBITDA Margin % | 31.79% | 31.42% | 30.19% | 32.63% | 33.9% | 34.73% | 31.38% | 28.2% | 29.55% |
EBITDA Growth % | 23.15% | 7.12% | 12.21% | 9.06% | 23.91% | 5.38% | -15.89% | -2.44% | 16.88% |
D&A (Non-Cash Add-back) | 81.9M | 77.4M | 114.6M | 135.4M | 163.3M | 166.8M | 144.9M | 155.2M | 156.6M |
EBIT | 1.06B | 794.8M | 1.19B | 938.9M | 1.73B | 1.79B | 1.39B | 1.57B | 1.27B |
Net Interest Income | -2.9M | -1.4M | 4.9M | 1.2M | -7.4M | 9.3M | 49.6M | 100.5M | 148.4M |
Interest Income | 20.3M | 32M | 32.2M | 23.4M | 17.4M | 35.5M | 67.2M | 120.3M | 148.4M |
Interest Expense | 23.2M | 33.4M | 27.3M | 22.2M | 24.8M | 26.2M | 17.6M | 19.8M | 0 |
Other Income/Expense | 24.8M | -330.9M | -31.4M | -379.3M | 91.6M | 65M | -54.9M | 169.4M | -363.3M |
Pretax Income | 1.03B▲ 0% | 761.4M▼ 26.4% | 1.17B▲ 53.2% | 916.7M▼ 21.4% | 1.7B▲ 85.7% | 1.77B▲ 3.8% | 1.37B▼ 22.3% | 1.55B▲ 12.8% | 1.27B▼ 17.8% |
Pretax Margin % | 30.13% | 20.45% | 26.83% | 20.9% | 32.53% | 32.84% | 27.39% | 28.46% | 20.98% |
Income Tax | 451.3M | 39.2M | 119.6M | 93.3M | 198.9M | 245.5M | 152.4M | 152.1M | 216.9M |
Effective Tax Rate % | 43.61% | 5.15% | 10.25% | 10.18% | 11.69% | 13.89% | 11.1% | 9.82% | 17.04% |
Net Income | 622.1M▲ 0% | 722.2M▲ 16.1% | 1.05B▲ 45.0% | 823.4M▼ 21.3% | 1.5B▲ 82.5% | 1.52B▲ 1.3% | 1.4B▼ 7.9% | 4.17B▲ 197.7% | 1.07B▼ 74.3% |
Net Margin % | 18.11% | 19.4% | 24.08% | 18.77% | 28.73% | 28.28% | 27.99% | 76.75% | 17.69% |
Net Income Growth % | 9.24% | 16.09% | 44.96% | -21.35% | 82.55% | 1.25% | -7.85% | 197.68% | -74.28% |
Net Income (Continuing) | 583.6M | 722.2M | 1.05B | 823.4M | 1.5B | 1.52B | 1.22B | 1.4B | 1.06B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 179.4M | 2.77B | 13.4M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 69.4M | 64.5M | 0 |
EPS (Diluted) | 0.96▲ 0% | 1.13▲ 17.7% | 1.64▲ 45.1% | 1.30▼ 20.7% | 2.38▲ 83.1% | 2.44▲ 2.5% | 2.30▼ 5.7% | 6.97▲ 203.0% | 1.83▼ 73.7% |
EPS Growth % | 10.34% | 17.71% | 45.13% | -20.73% | 83.08% | 2.52% | -5.74% | 203.04% | -73.74% |
EPS (Basic) | 0.98 | 1.15 | 1.68 | 1.32 | 2.41 | 2.46 | 2.31 | 6.98 | 1.84 |
Diluted Shares Outstanding | 647.7M | 640.8M | 636.6M | 631.9M | 631.2M | 624.2M | 609.4M | 599.3M | 585.8M |
Basic Shares Outstanding | 632.7M | 627.6M | 624.9M | 622.6M | 623.3M | 619M | 606.7M | 597.7M | 584.8M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
EW Balance Sheet
Edwards Lifesciences Corporation (EW) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.53B | 2.29B | 2.98B | 3.09B | 3.18B | 3.1B | 4.04B | 6.29B | 6.74B |
Cash & Short-Term Investments | 1.34B | 956.5M | 1.52B | 1.4B | 1.47B | 1.22B | 1.63B | 3.98B | 4.23B |
Cash Only | 818.3M | 714.1M | 1.18B | 1.18B | 862.8M | 769M | 1.13B | 3.05B | 2.94B |
Short-Term Investments | 519.2M | 242.4M | 337.8M | 219.4M | 604M | 446.3M | 500.5M | 930.7M | 1.29B |
Accounts Receivable | 479.3M | 537.3M | 599.1M | 602.8M | 664.9M | 699.1M | 828.1M | 727.4M | 912.1M |
Days Sales Outstanding | 50.93 | 52.68 | 50.29 | 50.16 | 46.38 | 47.41 | 60.33 | 48.81 | 54.87 |
Inventory | 554.9M | 607M | 640.9M | 802.3M | 726.7M | 875.5M | 903.5M | 1.09B | 1.13B |
Days Inventory Outstanding | 229.4 | 240.27 | 202.48 | 266.46 | 216.37 | 273.78 | 317.92 | 354.94 | 309.79 |
Other Current Assets | 116.9M | 131.8M | 168M | 208.2M | 237.1M | 195.9M | 542.5M | 374.4M | 338.8M |
Total Non-Current Assets | 3.16B | 3.04B | 3.5B | 4.15B | 5.32B | 5.2B | 5.33B | 6.77B | 6.96B |
Property, Plant & Equipment | 679.7M | 867.5M | 1.14B | 1.49B | 1.64B | 1.73B | 1.68B | 1.78B | 1.91B |
Fixed Asset Turnover | 5.05x | 4.29x | 3.81x | 2.95x | 3.19x | 3.12x | 2.99x | 3.05x | 3.17x |
Goodwill | 1.13B | 1.11B | 1.17B | 1.17B | 1.17B | 1.16B | 1.15B | 1.78B | 1.77B |
Intangible Assets | 468M | 343.2M | 336.5M | 331.4M | 323.6M | 285.2M | 399.4M | 1.18B | 1.13B |
Long-Term Investments | 567M | 506.3M | 585.5M | 801.6M | 1.83B | 1.24B | 583.9M | 307.9M | 773.9M |
Other Non-Current Assets | 108.9M | 33.6M | 101.8M | 119.6M | 110.8M | 299.1M | 774.3M | 732.4M | 234.9M |
Total Assets | 5.7B▲ 0% | 5.32B▼ 6.5% | 6.49B▲ 21.9% | 7.24B▲ 11.5% | 8.5B▲ 17.5% | 8.29B▼ 2.5% | 9.36B▲ 12.9% | 13.06B▲ 39.4% | 13.7B▲ 4.9% |
Asset Turnover | 0.60x | 0.70x | 0.67x | 0.61x | 0.62x | 0.65x | 0.54x | 0.42x | 0.44x |
Asset Growth % | 26.31% | -6.54% | 21.87% | 11.54% | 17.49% | -2.47% | 12.91% | 39.43% | 4.92% |
Total Current Liabilities | 1.4B | 876.6M | 902.4M | 893.9M | 1.03B | 1.02B | 1.2B | 1.51B | 1.81B |
Accounts Payable | 116.6M | 134M | 180.4M | 196.5M | 204.5M | 201.9M | 186.6M | 197.4M | 227.5M |
Days Payables Outstanding | 48.2 | 53.04 | 56.99 | 65.26 | 60.89 | 63.14 | 65.66 | 64.48 | 62.58 |
Short-Term Debt | 598M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.5M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53.7M | 27.2M |
Other Current Liabilities | 349.1M | 434M | 338.9M | 290.5M | 342.7M | 305M | 530.2M | 442.7M | 874.5M |
Current Ratio | 1.81x | 2.61x | 3.31x | 3.46x | 3.08x | 3.03x | 3.38x | 4.18x | 3.72x |
Quick Ratio | 1.41x | 1.92x | 2.60x | 2.56x | 2.38x | 2.17x | 2.62x | 3.45x | 3.09x |
Cash Conversion Cycle | 232.12 | 239.91 | 195.78 | 251.36 | 201.86 | 258.05 | 312.59 | 339.27 | 302.08 |
Total Non-Current Liabilities | 1.3B | 1.31B | 1.44B | 1.77B | 1.63B | 1.46B | 1.45B | 1.49B | 1.55B |
Long-Term Debt | 438.4M | 593.8M | 594.4M | 595M | 595.7M | 596.3M | 597M | 597.7M | 598.3M |
Capital Lease Obligations | 0 | 0 | 58.9M | 72.7M | 69.1M | 69.5M | 65.2M | 78.9M | 82.6M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 851.8M | 712.9M | 784.1M | 1.1B | 969.6M | 797.6M | 786.2M | 810.6M | 865M |
Total Liabilities | 2.7B | 2.18B | 2.34B | 2.66B | 2.67B | 2.49B | 2.64B | 2.99B | 3.36B |
Total Debt | 1.04B | 593.8M | 678.8M | 694.9M | 690.3M | 691.3M | 685.1M | 700M | 705.4M |
Net Debt | 218.1M | -120.3M | -500.3M | -488.3M | -172.5M | -77.7M | -447.2M | -2.35B | -2.23B |
Debt / Equity | 0.35x | 0.19x | 0.16x | 0.15x | 0.12x | 0.12x | 0.10x | 0.07x | 0.07x |
Debt / EBITDA | 0.95x | 0.51x | 0.52x | 0.49x | 0.39x | 0.37x | 0.44x | 0.46x | 0.39x |
Net Debt / EBITDA | 0.20x | -0.10x | -0.38x | -0.34x | -0.10x | -0.04x | -0.28x | -1.53x | -1.25x |
Interest Coverage | 45.61x | 23.80x | 43.73x | 42.29x | 69.63x | 68.46x | 78.98x | 79.19x | - |
Total Equity | 2.99B▲ 0% | 3.14B▲ 4.9% | 4.15B▲ 32.1% | 4.57B▲ 10.3% | 5.84B▲ 27.6% | 5.81B▼ 0.5% | 6.72B▲ 15.7% | 10.06B▲ 49.8% | 10.34B▲ 2.7% |
Equity Growth % | 14.35% | 4.87% | 32.09% | 10.27% | 27.58% | -0.5% | 15.72% | 49.76% | 2.73% |
Book Value per Share | 4.62 | 4.90 | 6.52 | 7.24 | 9.25 | 9.30 | 11.03 | 16.79 | 17.65 |
Total Shareholders' Equity | 2.99B | 3.14B | 4.15B | 4.57B | 5.84B | 5.81B | 6.65B | 10B | 10.34B |
Common Stock | 212M | 215.2M | 218.1M | 636.4M | 642M | 646.3M | 650.5M | 654.8M | 658.7M |
Retained Earnings | 2B | 2.69B | 3.74B | 4.57B | 6.07B | 7.59B | 8.99B | 13.17B | 14.24B |
Treasury Stock | -252.1M | -1.02B | -1.28B | -1.9B | -2.42B | -4.14B | -5.02B | -6.19B | -7.09B |
Accumulated OCI | -132.7M | -138.5M | -156M | -161.1M | -157.7M | -254.9M | -242.8M | -244.5M | -238.3M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 69.4M | 64.5M | 0 |
EW Cash Flow Statement
Edwards Lifesciences Corporation (EW) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1B | 926.8M | 1.18B | 1.05B | 1.73B | 1.22B | 895.8M | 542.3M | 1.6B |
Operating CF Margin % | 29.13% | 24.9% | 27.13% | 24.04% | 33.1% | 22.63% | 17.88% | 9.97% | 26.29% |
Operating CF Growth % | 42.06% | -7.38% | 27.26% | -10.61% | 64.29% | -29.67% | -26.47% | -39.46% | 194.15% |
Net Income | 583.6M | 722.2M | 1.05B | 823.4M | 1.5B | 1.52B | 1.4B | 4.17B | 1.07B |
Depreciation & Amortization | 81.9M | 77.4M | 89.3M | 107.2M | 134.8M | 139.6M | 144.9M | 155.2M | 156.6M |
Stock-Based Compensation | 61.6M | 71M | 81.3M | 92.6M | 109.3M | 126.8M | 139.4M | 162.3M | 158.1M |
Deferred Taxes | 17.8M | -27.3M | 12.1M | -49.4M | -41.4M | -254.5M | -272.1M | -323.4M | -117.6M |
Other Non-Cash Items | 21.6M | 126.1M | 154.1M | 38.3M | -119M | 105.8M | 7.5M | -3.36B | 174.1M |
Working Capital Changes | 234.2M | -42.6M | -204.3M | 42.2M | 145.3M | -421.4M | -526.3M | -259.3M | 154.6M |
Change in Receivables | -3.9M | -13M | -94.8M | 283.9M | -112.4M | -84.1M | -141.2M | 121.2M | -23M |
Change in Inventory | -124M | -65.7M | -105.4M | -120.6M | 19M | -213.4M | -289M | -256.1M | 50.7M |
Change in Payables | 85.2M | 192.5M | -63.5M | -84.5M | 195.2M | -21.4M | 146M | 89.5M | 395.1M |
Cash from Investing | -647.2M | 76.7M | -595.8M | -531.1M | -1.72B | 252.3M | 173.8M | 2.31B | -712.9M |
Capital Expenditures | -175.5M | -241.7M | -278.4M | -407.3M | -329.8M | -264.8M | -266.3M | -282.4M | -260.2M |
CapEx % of Revenue | 5.11% | 6.49% | 6.4% | 9.29% | 6.3% | 4.92% | 5.32% | 5.19% | 4.29% |
Acquisitions | -184.6M | -6.2M | -100.2M | 407.3M | 329.8M | 0 | -95.2M | -1.06B | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -43.1M | -4.8M | -24M | -446.4M | -359.3M | -63.1M | -75M | 3.75B | -195.7M |
Cash from Financing | -473.2M | -1.1B | -115.6M | -486.9M | -356.3M | -1.58B | -711M | -983M | -956.8M |
Debt Issued (Net) | 176.3M | -437.3M | -10M | -800K | -1.8M | -200K | -300K | 0 | 0 |
Equity Issued (Net) | -763.3M | -795.5M | -263.3M | -625.4M | -512.8M | -1.73B | -879.6M | -1.16B | -719.3M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -763.3M | -795.5M | -263.3M | -625.4M | -512.8M | -1.73B | -879.6M | -1.16B | -893.4M |
Other Financing | 113.8M | 131.6M | 157.7M | 139.3M | 158.3M | 142.8M | 168.9M | 176.4M | -237.5M |
Net Change in Cash | -111.8M▲ 0% | -104.2M▲ 6.8% | 465M▲ 546.3% | 15.8M▼ 96.6% | -332.8M▼ 2206.3% | -94.8M▲ 71.5% | 375.4M▲ 496.0% | 1.91B▲ 409.0% | -119.3M▼ 106.2% |
Free Cash Flow | 825.2M▲ 0% | 685.1M▼ 17.0% | 901M▲ 31.5% | 647M▼ 28.2% | 1.4B▲ 116.7% | 953.4M▼ 32.0% | 629.5M▼ 34.0% | 289.9M▼ 53.9% | 1.33B▲ 360.5% |
FCF Margin % | 24.02% | 18.4% | 20.72% | 14.75% | 26.8% | 17.71% | 12.56% | 5.33% | 22% |
FCF Growth % | 69.45% | -16.98% | 31.51% | -28.19% | 116.74% | -32.01% | -33.97% | -53.95% | 360.5% |
FCF per Share | 1.27 | 1.07 | 1.42 | 1.02 | 2.22 | 1.53 | 1.03 | 0.48 | 2.28 |
FCF Conversion (FCF/Net Income) | 1.61x | 1.28x | 1.13x | 1.28x | 1.15x | 0.80x | 0.64x | 0.13x | 1.49x |
Interest Paid | 19.9M | 30.1M | 19.9M | 19.9M | 20.2M | 19.3M | 19.9M | 19.6M | 0 |
Taxes Paid | 143.7M | 223.7M | 61.5M | 197.9M | 182.5M | 504.1M | 470.1M | 1.2B | 0 |
EW Key Ratios
Edwards Lifesciences Corporation (EW) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 22.24% | 22.16% | 23.54% | 28.73% | 18.88% | 28.88% | 26.14% | 22.39% | 49.75% | 10.52% |
Return on Invested Capital (ROIC) | 25% | 26.47% | 26.29% | 26.95% | 25.14% | 24.78% | 22.41% | 17.84% | 14.78% | 15.51% |
Gross Margin | 72.81% | 74.3% | 75.23% | 73.43% | 74.94% | 76.57% | 78.31% | 79.3% | 79.46% | 78.13% |
Net Margin | 19.22% | 18.11% | 19.4% | 24.08% | 18.77% | 28.73% | 28.28% | 27.99% | 76.75% | 17.69% |
Debt / Equity | 0.31x | 0.35x | 0.19x | 0.16x | 0.15x | 0.12x | 0.12x | 0.10x | 0.07x | 0.07x |
Interest Coverage | 41.99x | 45.61x | 23.80x | 43.73x | 42.29x | 69.63x | 68.46x | 78.98x | 79.19x | - |
FCF Conversion | 1.24x | 1.61x | 1.28x | 1.13x | 1.28x | 1.15x | 0.80x | 0.64x | 0.13x | 1.49x |
Revenue Growth | 18.85% | 15.91% | 8.37% | 16.79% | 0.88% | 19.29% | 2.86% | -6.92% | 8.57% | 11.55% |
Related:EW Dividend History·EW Revenue History·EW Price History·EW P/E History·EW Financial Ratios·EW Institutional Holders
EW SEC Filings & Documents
Edwards Lifesciences Corporation (EW) SEC filings — annual & quarterly reports (10-K, 10-Q)
EW Frequently Asked Questions
Edwards Lifesciences Corporation (EW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Edwards Lifesciences Corporation (EW) reported $6.07B in revenue for fiscal year 2025. This represents a 570% increase from $905.0M in 1999.
Edwards Lifesciences Corporation (EW) grew revenue by 11.5% over the past year. This is steady growth.
Yes, Edwards Lifesciences Corporation (EW) is profitable, generating $1.07B in net income for fiscal year 2025 (17.7% net margin).
Dividend & Returns
Edwards Lifesciences Corporation (EW) has a return on equity (ROE) of 10.5%. This is reasonable for most industries.
Edwards Lifesciences Corporation (EW) generated $1.33B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.